Pascal Soriot says 2020 approval still possible for AstraZeneca's Covid-19 vaccine as the world awaits the safety board's decision
Moderna was the first company to put a vaccine candidate into humans, but for much of the pandemic it was AstraZeneca and their academic partners at Oxford University putting out the most aggressive timelines. They signed deals with the UK promising to supply doses as early as September and Sarah Gilbert, the vaccine’s academic architect, talked, albeit cautiously, about getting efficacy data by that time.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.